Study Data | RA-ILD N (%) (n=54) | RA N (%) (n=678) | P-value § |
---|---|---|---|
Age at diagnosis of RA (mean ± SD) | 56.5 ± 13.7 | 46.4 ± 15.4 | < 0.001 ** |
Age at diagnosis of RA-ILD (mean ± SD) | 61.9 ± 12.2 | -- | -- |
Female gender | 42 (77.8%) | 608 (89.7%) | 0.008 ** |
Male gender | 12 (22.2%) | 70 (10.3%) | Â |
Smoking | Â | Â | Â |
 • Ever smoked | 09 (16.7%) | 20 (2.9%) | < 0.001 ** |
 • Never smoked | 45 (83.3%) | 658 (97.1%) | |
Comorbidities | Â | Â | Â |
 • DM | 23 (42.6%) | 130 (19.2%) | < 0.001 ** |
 • HTN | 26 (48.1%) | 171 (25.3%) | < 0.001 ** |
 • DLP | 04 (07.4%) | 57 (08.4%) | 0.793 |
 • Hypothyroidism | 11 (20.4%) | 91 (13.5%) | 0.159 |
 • IHD | 08 (14.8%) | 12 (01.8%) | < 0.001 ** |
 • OA | 10 (18.5%) | 63 (09.3%) | 0.030 ** |
 • Osteoporosis | 07 (13.0%) | 52 (07.7%) | 0.171 |
 • Others | 17 (56.7%) | 175 (68.6%) | 0.186 |
Seropositive | Â | Â | Â |
 • RF | 35 (71.4%) | 356 (59.9%) | 0.113 |
 • Anti-CCP | 31 (66.0%) | 334 (58.2%) | 0.298 |
 • Double positive | 03 (09.1%) | 50 (16.3%) | 0.279 |
 • Seronegative | 01 (03.0%) | 21 (06.8%) | 0.400 |
 • Antinuclear Antibody (ANA) | 24 (60.0%) | 332 (67.9%) | 0.306 |